DOBI Medical International Launches Enhanced Website
Website Provides An Array of New Company Information
Mahwah, NJ, July 20, 2004. DOBI Medical
International, Inc. (OTCBB DBMI.OB) today announced it has launched an
enhanced, more comprehensive version of its corporate website at
igaot.pt. The redesigned website provides in-depth
information about the Company and its ComfortScan™ system to a broad
spectrum of parties interested in breast health, including clinicians,
researchers, physicians, medical device distributors, and other
DOBI Medical is a development stage medical imaging company working to create a new means for the improved diagnosis of cancer through the detection of abnormal vascularization ("angiogenesis") associated with tumors. DOBI Medical’s first application of the technology is the ComfortScan system, a gentle, non-invasive, non-ionizing, dynamic optical imaging system designed to assist physicians in the detection and management of breast cancer. The ComfortScan system is intended to achieve this by providing new, physiology-based imagery of abnormal vascularization in the breast that are not readily available today. The DOBI Medical ComfortScan system is limited by U.S. law to investigational use. The product is not yet commercially available in the U.S. and its future availability in the U.S. cannot be ensured.
Cautionary Statement For Forward Looking Statements
Statements contained in this press release may contain information that includes or is based upon certain "forward-looking statements" relating to the business of DOBI Medical. These forward-looking statements represent management's current judgment and assumptions and can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements are frequently accompanied by the use of such words as "anticipates", "plans", "believes", "expects", "projects", "intends", or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties, including uncertainties relating to the timely and successful completion of our patient clinical trials and submission of our pre-market approval application to the FDA; final approval of our ComfortScan system by the FDA (several other medical device imaging companies have recently experienced delays in seeking FDA final approval); our ability to secure additional financing; success of product development efforts; our ability to timely meet federal, local and foreign government and industry regulations and standards; delays in the manufacturing process caused by our inabilities or the inabilities of our subcontractors to timely meet our specifications; our ability to establish international and domestic distribution networks, our ability to timely export our products to international markets; acceptance and use of our ComfortScan system by physicians, imaging clinics, and patients; our ability to obtain third party payer reimbursement; and our ability to compete on price and quality. Any one of these or other risks and uncertainties may cause actual results to be materially different from those described herein or elsewhere by us. Certain of these risks and uncertainties are or will be described in greater detail in our filings from time to time with the Securities and Exchange Commission, which we strongly urge you to read, including our 2003 Annual Report on Form 10-KSB and our Quarterly Report for the period ending March 31, 2004, which may be accessed on our website at igaot.pt. Subsequent written and oral forward looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements and risk factors set forth above and elsewhere in our reports filed with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward looking statement.
For further information:
DOBI Medical International